Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Open-label, add-on trial of cetirizine for neuromyelitis optica.

Katz Sand I, Fabian MT, Telford R, Kraus TA, Chehade M, Masilamani M, Moran T, Farrell C, Ebel S, Cook LJ, Rose J, Lublin FD.

Neurol Neuroimmunol Neuroinflamm. 2018 Feb 2;5(2):e441. doi: 10.1212/NXI.0000000000000441. eCollection 2018 Mar.

PMID:
30426035
2.

Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria.

Cekanaviciute E, Pröbstel AK, Thomann A, Runia TF, Casaccia P, Katz Sand I, Crabtree E, Singh S, Morrissey J, Barba P, Gomez R, Knight R, Mazmanian S, Graves J, Cree BAC, Zamvil SS, Baranzini SE.

mSystems. 2018 Nov 6;3(6). pii: e00083-18. doi: 10.1128/mSystems.00083-18. eCollection 2018 Nov-Dec.

3.

The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence.

Katz Sand I.

Curr Nutr Rep. 2018 Sep;7(3):150-160. doi: 10.1007/s13668-018-0236-z. Review.

4.

Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'.

Harel A, Sperling D, Petracca M, Ntranos A, Katz-Sand I, Krieger S, Lublin F, Wang Z, Liu Y, Inglese M.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):977-982. doi: 10.1136/jnnp-2017-317606. Epub 2018 Mar 16.

PMID:
29549189
5.

The microbiome and MS: The influence of the microbiota on MS risk and progression-Session chair summary.

Katz Sand I, Baranzini SE.

Mult Scler. 2018 Apr;24(5):587-589. doi: 10.1177/1352458518761167. Epub 2018 Mar 2. No abstract available.

PMID:
29498302
6.

The use of natalizumab for multiple sclerosis.

Brandstadter R, Katz Sand I.

Neuropsychiatr Dis Treat. 2017 Jun 28;13:1691-1702. doi: 10.2147/NDT.S114636. eCollection 2017. Review.

7.

Neuromyelitis Optica Spectrum Disorders.

Katz Sand I.

Continuum (Minneap Minn). 2016 Jun;22(3):864-96. doi: 10.1212/CON.0000000000000337. Review.

PMID:
27261687
8.

Classification, diagnosis, and differential diagnosis of multiple sclerosis.

Katz Sand I.

Curr Opin Neurol. 2015 Jun;28(3):193-205. doi: 10.1097/WCO.0000000000000206. Review.

PMID:
25887774
9.

Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD.

Brain. 2015 Mar;138(Pt 3):517-39. doi: 10.1093/brain/awu397. Epub 2015 Jan 29. Review.

10.

Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P.

Brain. 2014 Aug;137(Pt 8):2271-86. doi: 10.1093/brain/awu139. Epub 2014 Jun 3. Erratum in: Brain. 2015 Jul;138(Pt 7):e367.

11.

Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.

Katz Sand I, Krieger S, Farrell C, Miller AE.

Mult Scler. 2014 Oct;20(12):1654-7. doi: 10.1177/1352458514521517. Epub 2014 Feb 3.

PMID:
24493475
12.

Diagnosis and differential diagnosis of multiple sclerosis.

Katz Sand IB, Lublin FD.

Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):922-43. doi: 10.1212/01.CON.0000433290.15468.21. Review.

PMID:
23917094

Supplemental Content

Loading ...
Support Center